Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New tumor markers: CA125 and beyond.

R C Bast1, D Badgwell, Z Lu

  • 1University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. rbast@mdanderson.org

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|December 14, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heat increment of feeding in the common bottlenose dolphin (Tursiops truncatus) contributes moderately to field metabolic rate estimates.

The Journal of experimental biology·2025
Same author

Jewish cultural and religious factors and uptake of population-based BRCA testing across denominations: a cohort study.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Ranitidine for pruritus management in an infant.

Anaesthesia reports·2021
Same author

Paediatric extracorporeal membrane oxygenation and extracorporeal cardiopulmonary resuscitation.

BJA education·2021
Same author

Ultrasound elastography using a regularized modified error in constitutive equations (MECE) approach: a comprehensive phantom study.

Physics in medicine and biology·2020
Same author

Serial endometrial thickness and risk of non-endometrial hormone-dependent cancers in postmenopausal women in UK Collaborative Trial of Ovarian Cancer Screening.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2019

New biomarkers are crucial for early ovarian cancer detection and monitoring treatment response. CA125 is a key marker, but combining it with others like HE4 will improve early diagnosis and recurrence surveillance.

Area of Science:

  • Gynecologic Oncology
  • Biomarker Discovery
  • Translational Medicine

Background:

  • CA125 (MUC16) is an established serum tumor marker for ovarian cancer, aiding in chemotherapy response monitoring, recurrence detection, and differentiating benign from malignant pelvic masses.
  • Its rapid decline during chemotherapy correlates with a favorable prognosis and can inform clinical trial design, potentially serving as a surrogate marker in Phase II trials.
  • Serial CA125 measurements may also track disease stabilization with targeted therapies, but its greatest potential lies in early detection, where rising levels can prompt further investigation like transvaginal sonography (TVS).

Purpose of the Study:

  • To review the current role and future potential of serum biomarkers in ovarian cancer management, focusing on early detection, treatment monitoring, and recurrence surveillance.
  • To highlight the limitations of CA125 alone and the need for additional markers to improve screening sensitivity and specificity.

Related Experiment Videos

  • To discuss emerging proteomic approaches and mathematical techniques for developing and validating novel ovarian cancer biomarkers.

    • Main Methods:

    • Review of existing literature on CA125 and other serum biomarkers for ovarian cancer.
    • Discussion of proteomic strategies, including mass spectrometry and proteomic analysis, for biomarker identification.
    • Examination of multiplex platforms and mathematical modeling for analyzing marker combinations.

    Main Results:

    • CA125 is valuable for monitoring treatment response and recurrence but has limitations, as 20% of ovarian cancers express little or no CA125.
    • An algorithm using serial CA125 levels to assess ovarian cancer risk and guide TVS is under evaluation in a large UK trial.
    • Over 30 additional serum markers, including HE4, mesothelin, M-CSF, osteopontin, kallikreins, and soluble EGF receptor, are being investigated, with promising results from proteomic approaches.

    Conclusions:

    • While CA125 remains a critical tool, its limitations necessitate the development and validation of novel serum biomarkers for comprehensive ovarian cancer screening and management.
    • Combining multiple biomarkers using advanced analytical techniques holds significant promise for improving the sensitivity and specificity of early detection and recurrence monitoring.
    • Future advancements in biomarker discovery and assay technology are expected to enhance the ability to detect ovarian cancer earlier and more effectively, ultimately improving patient survival.